levodopa and benserazide

PreclinicalSmall molecule

UUniversity Hospital, Geneva

levodopa and benserazide is one of 7 small molecule programs targeting Aphasia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AphasiaActive, not recruiting

AphasiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Aphasia

#DrugCompanyPhaseTrials

Namenda

AbbVie

Approved

2 2

Aricept

Eisai

Approved

2 3

Keppra

Lexapro

1 5

Reminyl

WWim Janssens

Preclinical

1 6

Venlafaxine Hydrochloride

Teva

Preclinical

1 7

levodopa and benserazide

UUniversity Hospital, Geneva

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Aphasia1 trial

Effect of Dopaminergic Medication on Recovery of Aphasia

Completed·UUniversity Hospital, Geneva·N/A·NCT00941265·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for levodopa and benserazide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — levodopa and benserazide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for levodopa and benserazide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Geneva company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity Hospital, Geneva

levodopa and benserazide

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Aphasia1 trial

References

Drug Info

Quick Facts

Related News